bioAffinity Technologies $4M Private Placement

BioAffinity Technologies, Inc., a biotechnology company focused on noninvasive diagnostics and early cancer detection, announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules. The offering involved the sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock, along with two warrants to purchase up to 16,924,054 shares. The combined effective offering price was $0.4657 per pre-funded warrant and accompanying warrants, with gross proceeds of approximately $4.0 million. WallachBeth Capital LLC acted as the sole placement agent. The offering was conducted under Section 4(a)(2) of the Securities Act and/or Regulation D, and the securities have not been registered under the Securities Act. The company will provide customary registration rights for the underlying shares.